These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 32920054)

  • 1. Persistent dermal lesions in a patient with previous history of visceral leishmaniasis.
    Jaiteh MB; İnkaya AÇ; Üner A; Elçin G; Ergüven S; Kurtulan O; Harxhi A; Akova M
    Parasitol Int; 2021 Feb; 80():102197. PubMed ID: 32920054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
    Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
    Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimony susceptible
    Ghosh S; Verma A; Kumar D; Deep DK; Ramesh V; Salotra P; Singh R
    Microbiol Spectr; 2024 Jun; 12(6):e0402623. PubMed ID: 38712926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis.
    Ramesh V; Dixit KK; Sharma N; Singh R; Salotra P
    J Infect Dis; 2020 Feb; 221(4):608-617. PubMed ID: 31854451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.
    Rihl M; Stoll M; Ulbricht K; Bange FC; Schmidt RE
    J Infect; 2006 Jul; 53(1):e25-7. PubMed ID: 16274744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine.
    Kumar D; Ramesh V; Verma S; Ramam M; Salotra P
    Ann Trop Med Parasitol; 2009 Dec; 103(8):727-30. PubMed ID: 20030997
    [No Abstract]   [Full Text] [Related]  

  • 7. Advanced case of PKDL due to delayed treatment: A rare case report.
    Topno RK; Rabi Das VN; Kumar M; Madhukar M; Pandey K; Verma N; Agrawal K; Lal CS; Siddiqui NA; Bimal S; Das P
    PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008052. PubMed ID: 32203500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-Kala-Azar Dermal Leishmaniasis Without Previous History of Visceral Leishmaniasis.
    Hasnain G; Shomik MS; Ghosh P; Rashid MO; Hossain S; Hamano S; Mondal D
    Am J Trop Med Hyg; 2016 Dec; 95(6):1383-1385. PubMed ID: 27672208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
    Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
    Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case report on para-kala-azar dermal leishmaniasis: an unresolved mystery.
    Hasan MM; Proma SB; Hossain MS; Arifuzzaman M; Islam N; Siddique MAB; Amiruzzaman
    BMC Infect Dis; 2023 Dec; 23(1):885. PubMed ID: 38110894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-kala-azar dermal leishmaniasis and leprosy: case report and literature review.
    Trindade MA; Silva LL; Braz LM; Amato VS; Naafs B; Sotto MN
    BMC Infect Dis; 2015 Nov; 15():543. PubMed ID: 26592919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
    Bhandari V; Kulshrestha A; Deep DK; Stark O; Prajapati VK; Ramesh V; Sundar S; Schonian G; Dujardin JC; Salotra P
    PLoS Negl Trop Dis; 2012; 6(5):e1657. PubMed ID: 22629478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-kala-azar dermal leishmaniasis due to Leishmania infantum in an HIV-negative patient treated with miltefosine.
    Monge-Maillo B; Norman FF; Chamorro-Tojeiro S; Gioia F; Pérez-Molina JA; Chicharro C; Moreno J; López-Vélez R
    J Travel Med; 2022 Nov; 29(7):. PubMed ID: 34668558
    [No Abstract]   [Full Text] [Related]  

  • 14. Combination therapy with amphotericin-B and miltefosine for post-kala-azar dermal leishmaniasis: a preliminary report.
    Ramesh V; Avishek K; Sharma V; Salotra P
    Acta Derm Venereol; 2014 Mar; 94(2):242-3. PubMed ID: 23995012
    [No Abstract]   [Full Text] [Related]  

  • 15. Post-kala-azar dermal leishmaniasis with mucosal involvement: an unusual case presentation including successful treatment with miltefosine.
    Salam MA; Siddiqui MA; Nabi SG; Bhaskar KR; Mondal D
    J Health Popul Nutr; 2013 Jun; 31(2):294-7. PubMed ID: 23930349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A male preponderance in patients with Indian post kala-azar dermal leishmaniasis is associated with increased circulating levels of testosterone.
    Mukhopadhyay D; Mukherjee S; Ghosh S; Roy S; Saha B; Das NK; Chatterjee M
    Int J Dermatol; 2016 May; 55(5):e250-5. PubMed ID: 26536363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post Kala-Azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India.
    Burza S; Sinha PK; Mahajan R; Sanz MG; Lima MA; Mitra G; Verma N; Das P
    PLoS Negl Trop Dis; 2014; 8(1):e2611. PubMed ID: 24392171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring of Parasite Kinetics in Indian Post-Kala-azar Dermal Leishmaniasis.
    Moulik S; Chaudhuri SJ; Sardar B; Ghosh M; Saha B; Das NK; Chatterjee M
    Clin Infect Dis; 2018 Jan; 66(3):404-410. PubMed ID: 29020350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: a possible challenge to elimination program in India.
    Das VN; Pandey K; Singh D; Forwood C; Lal CS; Das P
    J Postgrad Med; 2013; 59(3):226-8. PubMed ID: 24029204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changing clinico-epidemiology of post-kala-azar dermal leishmaniasis (PKDL) in India: Results of a survey in four endemic states.
    Saurabh S; Roy P; Pandey DK; Ray D; Tarak S; Pandey R; Kumar D; Jamil S; Paulraj A; Kumar A; Dutta S
    J Vector Borne Dis; 2020; 57(2):161-169. PubMed ID: 34290161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.